<DOC>
	<DOCNO>NCT02849990</DOCNO>
	<brief_summary>This phase II trial study well androgen receptor antagonist ARN-509 , abiraterone acetate , prednisone , degarelix , indomethacin work treat patient prostate cancer spread start nearby tissue lymph node surgery . Androgen cause growth tumor cell . Hormone therapy use androgen receptor antagonist ARN-509 , abiraterone acetate , prednisone , degarelix , indomethacin may fight prostate cancer lower amount androgen body make and/or blocking use androgen tumor cell .</brief_summary>
	<brief_title>Androgen Receptor Antagonist ARN-509 , Abiraterone Acetate , Prednisone , Degarelix , Indomethacin Treating Patients With Localized Prostate Cancer Before Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . The rate pathologic complete response ( pCR ) ( i.e . evidence residual tumor ) assess prostatectomy specimen follow 3-months ( 12 week ) neoadjuvant androgen receptor antagonist ARN-509 ( ARN-509 ) , abiraterone acetate , degarelix indomethacin . SECONDARY OBJECTIVES : I . To determine negative margin rate assess prostatectomy specimen follow 3-months ( 12 week ) neoadjuvant ARN-509 , abiraterone acetate , degarelix indomethacin . II . To determine rate near pCR ( i.e . = &lt; 5 mm residual tumor ) assess prostatectomy specimen follow 3-months ( 12 week ) neoadjuvant ARN-509 , abiraterone acetate , degarelix indomethacin . III . To determine rate pathologic T3 disease assess prostatectomy specimen follow 3-months ( 12 week ) neoadjuvant ARN-509 , abiraterone acetate , degarelix indomethacin . IV . To determine rate nodal metastasis assess surgical lymph node specimens follow 3-months ( 12 week ) neoadjuvant ARN-509 , abiraterone acetate , degarelix indomethacin . V. To determine apoptotic index ( i.e . percentage tumor cell undergoing apoptosis ) determine cleave caspase-3 immunohistochemistry follow 3-months ( 12 week ) neoadjuvant ARN-509 , abiraterone acetate , degarelix indomethacin . VI . To determine proportion men receive adjuvant radiation therapy within 1-year prostatectomy . VII . To determine biochemical ( i.e . prostate-specific antigen [ PSA ] ) progression free survival estimate two year last patient accrue ( i.e . confirm PSA post-radical prostatectomy &gt; = 0.2 ng/mL ) . VIII . To determine overall survival estimate two year last patient accrue . IX . Safety assess incidence severity adverse event serious adverse event grade accord National Cancer Institute - Common Terminology Criteria Adverse Events ( CTCAE ) version 4.0 . X. Exploratory biomarker assessment . OUTLINE : Patients receive androgen receptor antagonist ARN-509 abiraterone acetate orally ( PO ) daily , prednisone PO twice per day ( BID ) indomethacin PO three time per day ( TID ) . Patients also receive degarelix subcutaneously ( SC ) day 1 every 4 week 3 dos . Treatment continue 12 week absence disease progression unacceptable toxicity . Patients undergo prostatectomy day 85 . After completion study treatment , patient follow 28 , 113 , 450 815 day .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Indomethacin</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Receptor Antagonists</mesh_term>
	<criteria>Willing able provide write informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Documented histologically confirm adenocarcinoma prostate Willing undergo prostatectomy primary treatment localized prostate cancer High risk prostate cancer ( per National Comprehensive Cancer Network [ NCCN ] criterion ) : Gleason score 810 T3a PSA &gt; 20 ng/mL veryhigh risk prostate cancer ( per NCCN criterion ) : T3bT4 Serum testosterone &gt; = 150 ng/dL Able swallow study drug whole Willing take abiraterone acetate empty stomach ( food consume least two hour one hour dose ) Agrees use condom ( even men vasectomy ) another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant study drug 3 month follow last dose study drug ; must also agree donate sperm study 3 month receive last dose study drug Medications know low seizure threshold ( see list prohibit med ) must discontinue substitute least 4 week prior study entry Prior local therapy treat prostate cancer ( e.g . radical prostatectomy , radiation therapy , brachytherapy ) Prior use ARN509 , abiraterone acetate degarelix Prior ongoing systemic therapy prostate cancer include , limited : Hormonal therapy ( example [ e.g . ] leuprolide , goserelin , triptorelin , degarelix ) Cytochrome P450 ( CYP ) 17 inhibitor ( e.g . ketoconazole ) Antiandrogens ( e.g . bicalutamide , nilutamide ) Second generation antiandrogens ( e.g . enzalutamide , ARN509 ) Immunotherapy ( e.g . sipuleucelT , ipilimumab ) Chemotherapy ( e.g . docetaxel , cabazitaxel ) Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule Absolute neutrophil count [ ANC ] &lt; 1500/mm^3 Platelet count &lt; 100,000/mm^3 Hemoglobin &lt; 9 g/dL Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; = 2.5 x ULN ; Note : subject Gilbert 's syndrome , total bilirubin &gt; 1.5 × ULN , measure direct indirect bilirubin direct bilirubin = &lt; 1.5 × ULN , subject may eligible Abnormal kidney function ( glomerular filtration rate GFR &lt; 45 mL/min ) Serum albumin &lt; 3 g/dL Serum potassium &lt; 3.5 mmol/L Seizure know condition may predispose seizure ( e.g . prior stroke within 1 year randomization , brain arteriovenous malformation , schwannoma , meningioma , benign central nervous system [ CNS ] meningeal disease may require treatment surgery radiation therapy ) Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( eg , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior randomization History stroke within last 5years History gastrointestinal ( GI ) bleed require transfusion History peptic ulcer disease require treatment within last 5years History asthma nonsteroidal antiinflammatory drug ( NSAID ) induce asthma classified 'mildpersistent ' bad ( base symptom occur 2 day per week ) Uncontrolled hypertension Gastrointestinal disorder affect absorption Active infection ( eg , human immunodeficiency virus [ HIV ] viral hepatitis ) Any chronic medical condition require high dose corticosteroid 10 mg prednisone/ prednisolone daily Any condition opinion investigator , would preclude participation study Child Pugh class B &amp; C Preexisting viral hepatitis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>